Neil Bell, an expert in clinical development, has joined Avacta Life Sciences Ltd as chief development officer to manage human studies of the company’s lead drug, a pro-doxorubicin compound. He joins from Autolus Therapeutics Plc where he managed multiple clinical studies across Europe and the US for cancer medicines. Before that, he was head of clinical operations at Daiichi-Sankyo Co Ltd in the build up to the approval of edoxaban, an anticoagulant.
Avacta announced the appointment on 11 August 2020.
Copyright 2020 Evernow Publishing Ltd